Efficacy and safety of exenatide as add‐on therapy for patients with type 2 diabetes with an intensive insulin regimen: A randomized double‐blind trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of exenatide as add‐on therapy for patients with type 2 diabetes with an intensive insulin regimen: A randomized double‐blind trial

Published:2020-10-30 Issue:2 Volume:23 Page:374-381
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Joubert Michael¹²^ORCID,Opigez Victoria¹,Pavlikova Barbora³⁴,Peyro Saint Paul Laure⁵,Jeandidier Nathalie⁶,Briant Anaïs R.⁵,Parienti Jean‐Jacques²⁵,Reznik Yves¹²^ORCID

Affiliation:

1. Diabetes Care Unit Caen University Hospital Caen France

2. Unicaen Caen France

3. First Department of Internal Medicine Charles University Hospital in Pilsen Pilsen Czech Republic

4. Charles University, Faculty of Medicine in Pilsen Pilsen Czech Republic

5. Clinical Research Unit Caen University Hospital Caen France

6. Diabetes Care Unit Strasbourg University Hospital Strasbourg France

Funder

AstraZeneca

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14225

Reference20 articles.

1. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

2. Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

3. Premixed vs basal-bolus insulin regimen in Type 2 diabetes: comparison of clinical outcomes from randomized controlled trials and real-world data

4. Biphasic vs basal bolus insulin regimen in Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

5. Glycemic Control During Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: Individual Patient Data Meta-analysis and Meta-regression of Randomized Controlled Trials

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of lifestyle and glucagon‐like peptide‐1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases;Alimentary Pharmacology & Therapeutics;2024-05-30

2. Treatment of type 2 diabetes mellitus with stem cells and antidiabetic drugs: a dualistic and future-focused approach;Human Cell;2023-12-01

3. Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: Systematic review and meta-analysis;Obesity Medicine;2022-10

4. Glucagon‐like peptide‐1 receptor agonist prescribing patterns in adolescents with type 2 diabetes;Diabetes, Obesity and Metabolism;2022-05

5. Association of glucagon-like peptide 1 analogs and agonists administered for obesity with weight loss and adverse events: a systematic review and network meta-analysis;eClinicalMedicine;2021-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3